NR4A1 and breast carcinoma: Furthermore, because claims are collected for the purpose of payment and not research, inherent limitations in our claims analysis included the potential for incorrect reporting of diagnosis codes, mixing patients with early-stage breast cancer with patients with MBC, missing information on hormone receptor status, misinterpreting disease-onset dates, misclassifying the line of therapy, and inaccurately estimating actual drug dosages and schedules.